Company: SXTPW
Filing Date: 2025-08-27
Form Type: DEF 14A
Source: 0001213900-25-080878
Chunk: 32

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-27
Form: DEF 14A
Chunk 32
---
 the amendment to the 2022 Plan to increase the number of shares available
under the 2022 Plan, we granted Ms. Landon a five-year option to purchase a total of 4,167 shares of our common stock with a per share
exercise price to be determined by the Board on the date of grant. The options had a cashless exercise price and vest annually over five
years, with the first vesting date being December 31, 3024. On September 26, 2024, the Board approved the grant of the options to Ms.
Landon at a per share exercise price of $6.85.

In December 2024, the
Board approved the grant of 105,000 options to Dr. Dow and 15,000 options to Mr. Miller as equity-based long-term incentive awards, which
vest in five equal tranches on the last date of each fiscal year over five years, with the first vesting date being December 31, 2024.
The options were granted on January 2, 2025 with a per share exercise price of $6.55, the closing stock price on the grant date, and have
a seven-year term.

<div align='center'>18</div>

Employment Agreements

Dow Employment Agreement. We entered into an Employment Agreement dated as of January 12, 2023, with Geoffrey Dow (the “Dow Employment
Agreement”), our Chief Executive Officer and Chairman of our Board. The term of the Dow Employment Agreement began on January 12,
2023 for an initial period of two years, with subsequent automatic renewals unless either party thereto provides notice to terminate at
least 90 days prior to the applicable renewal date. The Dow Employment Agreement provides Dr. Dow an annual base salary of $228,000, bonuses
to the extent certain events occur or if applicable performance goals are met and employee benefits that are generally given to our senior
executives. In December 2024, the Board approved an increase to Dr. Dow’s base salary to $250,000 beginning in fiscal year 2025.
Contingent on the receipt of shareholder approval to increase the number of shares available under the 2022 Plan, Dr. Dow was granted
a five-year option to purchase a total of 250 shares of our common stock that vest on the last day of each quarter in each calendar year
(for a cumulative total or no more than 5,000 shares over five years). The